[go: up one dir, main page]

ES2100240T3 - Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen. - Google Patents

Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen.

Info

Publication number
ES2100240T3
ES2100240T3 ES91919303T ES91919303T ES2100240T3 ES 2100240 T3 ES2100240 T3 ES 2100240T3 ES 91919303 T ES91919303 T ES 91919303T ES 91919303 T ES91919303 T ES 91919303T ES 2100240 T3 ES2100240 T3 ES 2100240T3
Authority
ES
Spain
Prior art keywords
bacteriophagus
vaccines
modified
contain
genetic engineering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919303T
Other languages
English (en)
Inventor
Richard Nelson Perham
Anne Elizabeth Willis
Judith Greenwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2100240(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Application granted granted Critical
Publication of ES2100240T3 publication Critical patent/ES2100240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

UN BACTERIOFAGO FILAMENTOSO QUE INCLUYE, POR LO MENOS EN UNA PROPORCION DE SU PROTEINA DE REVESTIMIENTO PRINCIPAL, UN PEPTIDO EXTRAÑO DE 6 AMINOACIDOS POR LO MENOS QUE ES CAPAZ DE PROVOCAR UNA RESPUESTA BIOLOGICA. POR EJEMPLO, SI SE INCORPORA UN PEPTIDO INMUNOGENICO, SE PUEDE OBTENER UNA VACUNA EFECTIVA CONTRA LA MALARIA, ENFERMEDADES DE LOS PIES Y DE LA BOCA Y OTRAS INFECCIONES.
ES91919303T 1990-10-12 1991-10-14 Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen. Expired - Lifetime ES2100240T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022190A GB9022190D0 (en) 1990-10-12 1990-10-12 Immunogenic material

Publications (1)

Publication Number Publication Date
ES2100240T3 true ES2100240T3 (es) 1997-06-16

Family

ID=10683613

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919303T Expired - Lifetime ES2100240T3 (es) 1990-10-12 1991-10-14 Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen.

Country Status (9)

Country Link
EP (1) EP0552267B1 (es)
JP (1) JPH06501848A (es)
AT (1) ATE149202T1 (es)
DE (1) DE69124800T2 (es)
DK (1) DK0552267T3 (es)
ES (1) ES2100240T3 (es)
GB (1) GB9022190D0 (es)
GR (1) GR3023393T3 (es)
WO (1) WO1992007077A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
EP0580737B1 (en) * 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1995005454A1 (en) * 1992-02-22 1995-02-23 Cambridge Bacteriophage Technologies Ltd. Engineered bacteriophages and vaccines containing them
AU685753B2 (en) * 1992-09-04 1998-01-29 Scripps Research Institute, The Phagemids coexpressing a surface receptor and a surface heterologous protein
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
SE9803993D0 (sv) * 1998-11-23 1998-11-23 Bjoern Carlsson New reagent and use thereof
WO2000034482A2 (en) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Novel compounds derived from neisseria meningitidis
ES2337650T3 (es) 1999-03-12 2010-04-28 Glaxosmithkline Biologicals S.A. Polipeptidos antigenicos de neisseria meningitidis polinucleotidos y anticuerpos protectores correspondientes.
ES2344189T3 (es) 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
EP1088889A1 (en) * 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage
WO2001062778A2 (en) 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
US20030148380A1 (en) 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20050064508A1 (en) 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AU2006251098B2 (en) * 2005-05-26 2011-09-15 Kuros Us Llc Scalable fermentation process
EP1746165A1 (en) * 2005-07-21 2007-01-24 Cytos Biotechnology AG Scalable fermentation process
EP1726642A1 (en) * 2005-05-26 2006-11-29 Cytos Biotechnology AG Large-scale fermentation process for bacteriophages
NZ569417A (en) 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
CN113637696A (zh) * 2021-06-24 2021-11-12 新乡学院 一种用于pviii蛋白展示外源肽的噬菌粒载体及其构建方法

Also Published As

Publication number Publication date
JPH06501848A (ja) 1994-03-03
GR3023393T3 (en) 1997-08-29
GB9022190D0 (en) 1990-11-28
EP0552267B1 (en) 1997-02-26
DK0552267T3 (da) 1997-07-21
DE69124800D1 (de) 1997-04-03
ATE149202T1 (de) 1997-03-15
WO1992007077A1 (en) 1992-04-30
EP0552267A1 (en) 1993-07-28
DE69124800T2 (de) 1997-07-31

Similar Documents

Publication Publication Date Title
ES2100240T3 (es) Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen.
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
CO5280094A1 (es) Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo
MX166499B (es) Interferon recombinante inmune humano y composicion farmaceutica que lo incluye
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
BR9500732B8 (pt) Kit diagnóstico para a detecção de anticorpos contra vírus que causam imunodeficiência.
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
ATE153071T1 (de) Neue proteinhaltige partikeln
DK0975761T3 (da) Humant, rekombinant beta-interferon med forbedret opløselighed
MX9304803A (es) Vacuna de virus de hepatitis a.
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
DK0412766T3 (da) Peptidfragmenter af HIV
SE9002684D0 (sv) New peptides and their use
KR890006253A (ko) 가금류내의 E.coli septicaemia에 대한 백신
EP1131338A4 (en) PROCESS FOR PRODUCING HIGHLY PURIFIED INVASINATED PROTEIN AND USE OF SUCH PROTEIN
ES2078642T3 (es) Vacuna recombinante contra la enfermedad de marek.
ES2091159A1 (es) Antigeno recombinante, rsm14, procedente de schistosoma mansoni, su obtencion y utilizacion.
PT99923A (pt) Processo para a preparacao de proteinas hibridas de plasmodium falciparum que contem sequencias dos antigenios da malaria hrpii e serp e de composicoes farmaceuticas que contem estas proteinas
ES2176363T3 (es) Peptidos de la proteina gag del vih, su preparacion y su uso.
YU64192A (sh) Analozi insulina
MY104081A (en) Rhoptry membrane antigen of plasmodium falciparum.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552267

Country of ref document: ES